EYPT - EyePoint Pharma reports positive EYP-1901 results in wet-AMD

EyePoint Pharmaceuticals (EYPT) announces positive safety results from Phase 1 trial of EYP-1901, an anti-VEGF treatment targeting wet age-related macular degeneration (wet AMD). The DAVIO clinical trial of EYP-1901 enrolled 17 wet AMD patients across three dose cohorts.Key safety observations through at least 30-Day post-dosing follow-up include:No serious adverse events (SAEs), ocular or systemic, or adverse events related to significant intraocular inflammation, best-corrected visual acuity ((BCVA)) reduction were reported.The three subjects in cohort 1 have been followed for a minimum of four months with no reported SAE’s.No events of endophthalmitis, retinal detachment or migration into the anterior chamber have been reported to date The primary endpoint of trial is safety, and key secondary endpoints are BCVA and central subfield thickness.

For further details see:

EyePoint Pharma reports positive EYP-1901 results in wet-AMD